期刊文献+

噬菌体对结核病模型豚鼠免疫功能的影响 被引量:5

Effect of Bacteriophage D29 on the Immune Function of Guinea Pigs with a Model of Tuberculosis
暂未订购
导出
摘要 目的观察噬菌体D29对结核病模型豚鼠体液免疫功能与细胞免疫功能的影响。方法采用皮下攻击法建立敏感和耐药结核分枝杆菌感染的结核病豚鼠模型,分别将感染敏感菌和耐药菌的豚鼠随机分为对照组、噬菌体组、利福平(RFP)组和联合化疗组。对照组给予0.9%氯化钠溶液隔日灌胃;RFP组给予RFP溶液隔日灌胃,每次给药剂量为15mg·kg^-1,每周3次;联合化疗组采用RFP+乙胺丁醇+吡嗪酰胺+左氧氟沙星隔日灌胃,4种药物的剂量分别为15,25,25,6mg·kg^-1,每周3次;噬菌体组采用滴鼻的方式隔日给予噬菌体,每次1×10^8PFU(0.5mL),每周3次。均共治疗4~7周。观察治疗期间豚鼠血清中噬菌体中和抗体的动态变化,以及实验开始4周后豚鼠血清中白细胞介素.2(IL-2)、IL-4、γ干扰素(IFN-γ)的变化,并在电镜下观察巨噬细胞对噬菌体的吞噬情况。结果结核病模型豚鼠采用噬菌体治疗18d后,血清中均开始出现噬菌体中和抗体,抗体滴度与时间呈正相关。电镜观察发现巨噬细胞可以吞噬、消化部分噬菌体。敏感结核分枝杆菌感染模型采用利福平或噬菌体治疗4周后,血清中IL-2含量高于对照组;耐药结核分枝杆菌感染模型中RFP组、噬菌体组和联合化疗组的IL-2含量均高于对照组,其中噬菌体组血清IL-2含量最高,与对照组比较,差异有显著性(P〈0.05)。各组IL-4、IFN-γ均差异无显著性。结论噬菌体具有抗原的特性,可刺激机体产生中和抗体,同时可改善机体的细胞免疫功能,协同噬菌体杀灭机体内的结核分枝杆菌。 Objective To observe the effect of bacteriophage D29 on the humoral as well as cellular immune function of guinea pigs with a model of tuberculosis. Methods Guinea pig models of drug-sensitive and drug-resistant tuberculosis were set up by using the method of subcutaneous challenge with the corresponding bacteria. The animals infected with drug-sensitive or drug-resistant bacteria were then randomly divided into the following groups respectively: the control group, bacterophage group, rifampin(RFP) group and combined chemotherapy group. Guinea pigs of the control group were given each 0.9% sodium chloride solution administered by gastrogavage q. o. d.. Those of the RFP group were given each RFP solution containing 15 mg·kg^-1 of the drug administered by gastrogavage 3 times a week. Animals of the combined chemotherapy group were given each RFP + ethambutol + pyrazinamide + levofloxacin administered by gastrogavage q. o. d. , the doses of the 4 drugs being 15,25,25 and 6 mg·kg^-1, respectively. Guinea pigs of the bacteriophage group were given each 1×10s PFU(0.5 mL) of bacteriophage D29 administered by nasal dripping 3 times a week. The course of treatment in all 4 groups lasted 4 - 7 weeks. The dynamic changes in the serum titer of neutralizing antibodies against the bacteriophage in animals of the bacteriophage group, the changes in serum levels of IL-1, IL-4, IFN-T in animals of all 4 groups 4 weeks after the beginning of the experiment were kept under observation. Phagocytosis of the bacteriophage by the macrophage was examined with electron microscopy. Results Neutralizing antibodies against the bacteriophage began to appear in the sera of the guinea pigs after they had been treated with the bacteriophage for 18 days and the titers of the antibodies were positively correlated with the time. Macrophages were shown to phagocytize and digest a portion of the bacteriophages as revealed by electron microscopy. The serum IL-2 contents in guinea pigs with the model of drug-sensitive tubercle bacilli infection were greater than those of the control animals after the former had been treated with RFP or the bacteriophage for 4 weeks. The serum IL-2 contents in guinea pigs with the drug-resistant tubercle bacilli infection were greater in those animals treated with RFP, bacteriophage and combined chemotherapy as compared with those in control animals. Among these, animals treated with the bacteriophage had the highest serum IL-2 content as compared with that of the controls (P〈0.05 ). Differences between the different groups of animals with respect to serum IL-4 and IFN-γ levels were insignificant. Conclusion The bacteriophage was shown to be provided with antigenic characteristics. It could stimulate the organism to produce neutralizing antibodies and promote the cellular immune function of the body so that the latter could act svnergetically with the bacteriophage in the elimination of tubercle bacilli in the organism.
出处 《医药导报》 CAS 2006年第8期767-770,共4页 Herald of Medicine
关键词 噬菌体 结核分枝杆菌 豚鼠 免疫功能 Baterio phage Tubercle bacilli Guinea pig Immune function
  • 相关文献

参考文献7

  • 1Smiths H W, Huggine M B. The control of experimental diarrhea in calves by means of bcteriophage [ J ]. J Gen Microbiol,1987,133(5) :1111 - 1126.
  • 2彭丽,罗永艾,王国治.噬菌体生物扩增法快速检测结核分枝杆菌标准化研究[J].中华结核和呼吸杂志,2004,27(12):806-810. 被引量:23
  • 3彭丽,陈保文,罗永艾,沈小兵,黎友伦,王国治.利用噬菌体杀灭巨噬细胞内耻垢分枝杆菌的实验研究[J].中华结核和呼吸杂志,2005,28(9):619-622. 被引量:9
  • 4Turner O C, Basaraba R J, Orme I M. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with mycobacterium tuberculosis [ J ]. Infect Immun,2003,71 ( 2 ):864 - 871.
  • 5Merril C R, Biswas B, Carlton R, et al. Long-circulating bacteriophages as antibacterial agents [ J ]. Proc Natl Acad Sci USA, 1996,93(4) :3188 - 3192.
  • 6Lawrance B, Danuts S, Elizabeth M,et al. Killing of mycobacterium avium and mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens [ J ]. J Infect Dis ,2002,186 ( 16 ) : 1155 - 1166.
  • 7Lowrie D B,Tascon R E,Colston M J,et al. Towards a DNA vaccine against tuberculosis [ J ]. Vaccine, 1994, 12 ( 16 ) :1537 - 1540.

二级参考文献19

  • 1McNerney R, Wilson SM, Sidhu AM, et al. Inactivation of mycobacteriophage D29 using ferrous ammonium sulphate as a tool for the detection of viable Mycobacterium smegmatis and Mycobacterium tuberculosis. Res Microbiol, 1998,149: 487-495.
  • 2Eltringham IJ, Wilson SM, Drobnieski FA. Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as a rapid screen for rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide and ciprofloxacin among clinical
  • 3McNerney R. TB: the return of the phage .A review of fifty years of mycobacteriophage research. Int J Tuberc Lung Dis, 1999,3: 179-184.
  • 4Wilson SM, al-Suwaidi, McNerney R, et al. Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis. Nat Med, 1997,3: 465-468.
  • 5Seaman T, Trollip A, Mole R, et al. The use of a novel phage-based technology as a practical tool for the diagnosis of tuberculosis in Africa. African J Biotech, 2003, 2: 40-45.
  • 6Dye C, Garnett GP, Sleeman K, et al. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet, 1998,352:1886-1891.
  • 7Watterson SA, Wilson SM, Yates MD, et al. Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol, 1998, 36: 1969-1973.
  • 8Eltringham IJ, Drobniewski FA, Mangan JA, et al. Evaluation of reverse transcription-PCR and a bacteriophage-based assay for rapid phenotypic detection of rifampin resistance in clinical isolates of Mycobacterium tuberculosis. J Clin Microbiol, 1999, 37:
  • 9Marei AM, EI-Behedy EM, Mohtady HA, et al. Evaluation of a rapid bacteriophage-based method for the detection of Mycobacterium tuberculosis in clinical samples. J Med Microbiol, 2003, 54: 331-335.
  • 10Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother, 2001,45: 649-659.

共引文献30

同被引文献65

  • 1彭丽,罗永艾,沈小兵,王国治.分枝杆菌噬菌体生物学特性探讨[J].微生物学免疫学进展,2005,33(1):19-23. 被引量:5
  • 2郑玲,谷焰,伍建容,方道硕,王晓毓,张鸿彬.红景天在肿瘤患者化疗中的免疫功能调节作用[J].四川肿瘤防治,2007,20(1):30-32. 被引量:10
  • 3SUGITA K, TSUDA T, SAKAKIBARA T, et al. Studies on the bacteriophage susceptibility against mycobacterium tuberculosis. 1. The difference in lysis range of mycobacteriophage propagated on various host strains [ J ]. Yokohama Med Bull, 1965,16 ( 6 ) : 229 - 235.
  • 4LAWRANCE B, DANUTS S, ELIZABETH M,et al. Killing of mycobacterium avium and mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens [ J ]. J Infect Dis, 2002, 186(16) :1155 -1166.
  • 5FORD ME, SARKIS GJ, BELANGER AE, et al. Genome structure of mycobacteriophage D29: implications for phage evolution [ J ]. J Mol Biol, 1998, 279 ( 1 ) : 143 - 164.
  • 6NAKAI T, PARK SC. Bacteriophage therapy of infectious diseases in aquaculture [ J ]. Res Microbiol,2002,153 ( 1 ) : 13 - 18.
  • 7WEBER-DABROWSKA B, MULCZYK M ,GO'RSKI A. Bacterio- phage therapy for infections in cancer patients [ J ]. Clin Appl Immunol Rev,2001,3 -4(1 ) :131 - 134.
  • 8MERRIL CR, SCHOLL D, ADHYA SL. The prospect for bateriophage therapy in Western medicine[ J]. Nat Rev Drug Discov, 2003,2(6) :489 -497.
  • 9PLATT R, REYNOLDS DL, PHILLIPS GJ. Development of a novel method of lytic phage delivery by use of a bacteriophage P22 site-specific recombination system [ J ]. FEMS Microbiol Lett, 2003,223 (2) :259 - 265.
  • 10SMITHS HW, HUGGINE MB. The control of experimental diarrhea in calves by means of bcteriophage [ J ]. J Gen Microbiol, 1987, 133(5): 1111-1126.

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部